Next 10 |
home / stock / ipcif / ipcif news
TORONTO, ON / ACCESSWIRE / March 13, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) - (" Intellipharmaceutics " or the " Company "), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-rel...
TORONTO, ON / ACCESSWIRE / February 26, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) (" Intellipharmaceutics " or the " Company "), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-re...
TORONTO, ON / ACCESSWIRE / February 8, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release...
2024-01-02 17:54:30 ET More on Intellipharmaceutics Financial information for Intellipharmaceutics International For further details see: Intellipharmaceutics receives conditional approval to list on the TSX Venture Exchange
TORONTO, ON / ACCESSWIRE / January 2, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) - ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-releas...
2023-10-16 17:30:52 ET More on Intellipharmaceutics International Financial information for Intellipharmaceutics International For further details see: Intellipharmaceutics International GAAP EPS of -$0.06
TORONTO, ON / ACCESSWIRE / October 16, 2023 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-relea...
JPMorgan Chase & Co. (JPM) is expected to report $3.89 for Q3 2023 Unity Bancorp Inc. (UNTY) is expected to report $0.89 for Q3 2023 Wells Fargo & Company (WFC) is expected to report $1.25 for Q3 2023 Intellipharmaceutics International Inc (IPCIF) is expected to report for Q1 ...
Intellipharmaceutics International Inc (IPCIF) is expected to report for Q1 2024
2023-07-17 10:55:47 ET Intellipharmaceutics International press release ( OTC:IPCIF ): Q2 GAAP EPS of $0.00. Revenue of $480.21M. For further details see: Intellipharmaceutics International GAAP EPS of $0.00, revenue of $480.21M
News, Short Squeeze, Breakout and More Instantly...
Intellipharmaceutics International Inc Company Name:
IPCIF Stock Symbol:
OTCMKTS Market:
TORONTO, ON / ACCESSWIRE / March 13, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) - (" Intellipharmaceutics " or the " Company "), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-rel...
TORONTO, ON / ACCESSWIRE / February 26, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) (" Intellipharmaceutics " or the " Company "), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-re...
TORONTO, ON / ACCESSWIRE / February 8, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release...